180 related articles for article (PubMed ID: 25296595)
1. The role of tiopronin for the prevention of chemotherapy-related liver toxicity in advanced colorectal cancer patients treated with mFOLFOX7: a prospective analysis.
Li XP; Wen F; Yang W; Deng YB; Li M; Zhang PF; Tang RL; Li Q; Wei YQ
Tumori; 2014; 100(4):446-51. PubMed ID: 25296595
[TBL] [Abstract][Full Text] [Related]
2. The role of S-adenosyl methionine in preventing FOLFOX-induced liver toxicity: a retrospective analysis in patients affected by resected colorectal cancer treated with adjuvant FOLFOX regimen.
Vincenzi B; Santini D; Frezza AM; Berti P; Vespasiani U; Picardi A; Tonini G
Expert Opin Drug Saf; 2011 May; 10(3):345-9. PubMed ID: 21406026
[TBL] [Abstract][Full Text] [Related]
3. Prospective analysis of tiopronin in prevention of sorafenib and antiviral therapy inducing liver toxicity in advanced hepatitis B virus-related hepatocellular carcinoma.
Li J; Qiu X; Guo W; Yan B; Zhang S
Med Oncol; 2015 Oct; 32(10):238. PubMed ID: 26330362
[TBL] [Abstract][Full Text] [Related]
4. Toxicity during l-LV/5FU adjuvant chemotherapy as a modified RPMI regimen for patients with colorectal cancer.
Hotta T; Takifuji K; Arii K; Yokoyama S; Matsuda K; Higashiguchi T; Tominaga T; Oku Y; Yamaue H
Oncol Rep; 2005 Aug; 14(2):433-9. PubMed ID: 16012727
[TBL] [Abstract][Full Text] [Related]
5. [Magnesium isoglycyrrhizinate prevention of chemotherapy-induced liver damage during initial treatment of patients with gastrointestinal tumors].
Yan Y; Mo Y; Zhang D
Zhonghua Gan Zang Bing Za Zhi; 2015 Mar; 23(3):204-8. PubMed ID: 25938834
[TBL] [Abstract][Full Text] [Related]
6. Liver toxicity in colorectal cancer patients treated with first-line FOLFIRI-containing regimen: a single institution experience.
Vincenzi B; Imperatori M; Picardi A; Vespasiani Gentilucci U; Gallo P; Fausti V; Spalato Ceruso M; Santini D; Tonini G
Expert Rev Anticancer Ther; 2015; 15(8):971-6. PubMed ID: 26112080
[TBL] [Abstract][Full Text] [Related]
7. The role of S-adenosylmethionine in preventing oxaliplatin-induced liver toxicity: a retrospective analysis in metastatic colorectal cancer patients treated with bevacizumab plus oxaliplatin-based regimen.
Vincenzi B; Daniele S; Frezza AM; Berti P; Vespasiani U; Picardi A; Tonini G
Support Care Cancer; 2012 Jan; 20(1):135-9. PubMed ID: 21229271
[TBL] [Abstract][Full Text] [Related]
8. The value of serum aspartate aminotransferase and gamma-glutamyl transpetidase as biomarkers in hepatotoxicity.
Robles-Diaz M; Garcia-Cortes M; Medina-Caliz I; Gonzalez-Jimenez A; Gonzalez-Grande R; Navarro JM; Castiella A; Zapata EM; Romero-Gomez M; Blanco S; Soriano G; Hidalgo R; Ortega-Torres M; Clavijo E; Bermudez-Ruiz PM; Lucena MI; Andrade RJ; ;
Liver Int; 2015 Nov; 35(11):2474-82. PubMed ID: 25809419
[TBL] [Abstract][Full Text] [Related]
9. Incidence of liver toxicity associated with the use of flutamide in prostate cancer patients.
Gomez JL; Dupont A; Cusan L; Tremblay M; Suburu R; Lemay M; Labrie F
Am J Med; 1992 May; 92(5):465-70. PubMed ID: 1349790
[TBL] [Abstract][Full Text] [Related]
10. Palliative second-line treatment with weekly high-dose 5-fluorouracil as 24-hour infusion and folinic acid (AIO) plus oxaliplatin after pre-treatment with the AIO-regimen in colorectal cancer (CRC).
Link K; Happich K; Schirner I; Jüngert B; Brückl V; Männlein G; Brückl WM; Merkel S; Göhl J; Hohenberger W; Hahn EG; Wein A
Anticancer Res; 2004; 24(1):385-91. PubMed ID: 15015625
[TBL] [Abstract][Full Text] [Related]
11. A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy.
Hecht JR; Pillai M; Gollard R; Heim W; Swan F; Patel R; Dreiling L; Mo M; Malik I
Clin Colorectal Cancer; 2010 Apr; 9(2):95-101. PubMed ID: 20378503
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of risk factors for antituberculosis treatment induced hepatotoxicity.
Singla R; Sharma SK; Mohan A; Makharia G; Sreenivas V; Jha B; Kumar S; Sarda P; Singh S
Indian J Med Res; 2010 Jul; 132():81-6. PubMed ID: 20693595
[TBL] [Abstract][Full Text] [Related]
13. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
[TBL] [Abstract][Full Text] [Related]
14. [Clinical significance of bolus 5-fluorouracil for recurrent or metastatic colorectal cancer treated with FOLFOX+ BevacizumabTherapy].
Yoshida Y; Hasegawa J; Nishimura J; Hirota M; Kim Y; Nezu R
Gan To Kagaku Ryoho; 2011 Aug; 38(8):1293-6. PubMed ID: 21829066
[TBL] [Abstract][Full Text] [Related]
15. Folfox4 regimen administered through combined hepatic arterial and systemic infusion for treatment of colorectal cancer with unresectable liver metastases.
Guan M; Chen SC; Ying HY; Zhao L; Li XY; Zhou JF; Shao YJ; Yang XD; Lin Y; Ning XH; Bai CM
Chin Med J (Engl); 2012 Oct; 125(20):3640-5. PubMed ID: 23075717
[TBL] [Abstract][Full Text] [Related]
16. Aidi injection combined with FOLFOX4 chemotherapy regimen in the treatment of advanced colorectal carcinoma.
Wang T; Nan H; Zhang C; Wang Y; Zhang X; Li Y;
J Cancer Res Ther; 2014 Aug; 10 Suppl 1():52-5. PubMed ID: 25207892
[TBL] [Abstract][Full Text] [Related]
17. Biochemical liver function test parameter levels in relation to treatment response in liver metastatic colorectal patients treated with FOLFOX4 with or without bevacizumab.
Denić K; Tarabar D; Obradovic S; Ristić M; Spasić J; Radosavljević D; Ugrešić N
Srp Arh Celok Lek; 2016; 144(11-12):615-20. PubMed ID: 29659222
[TBL] [Abstract][Full Text] [Related]
18. Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study.
Santini D; Vincenzi B; Schiavon G; Di Seri M; Virzí V; Spalletta B; Caricato M; Coppola R; Tonini G
Cancer Chemother Pharmacol; 2007 Apr; 59(5):613-20. PubMed ID: 16944151
[TBL] [Abstract][Full Text] [Related]
19. A meta-analysis of chemotherapy regimen fluorouracil/leucovorin/oxaliplatin compared with fluorouracil/leucovorin in treating advanced colorectal cancer.
Chen ML; Fang CH; Liang LS; Dai LH; Wang XK
Surg Oncol; 2010 Mar; 19(1):38-45. PubMed ID: 19345093
[TBL] [Abstract][Full Text] [Related]
20. Circulating liver function markers and colorectal cancer risk: A prospective cohort study in the UK Biobank.
He MM; Fang Z; Hang D; Wang F; Polychronidis G; Wang L; Lo CH; Wang K; Zhong R; Knudsen MD; Smith SG; Xu RH; Song M
Int J Cancer; 2021 Apr; 148(8):1867-1878. PubMed ID: 33091956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
